Ladenburg analyst Matthew Kaplan raised the firm’s price target on United Therapeutics to $268 from $256 and keeps a Buy rating on the shares following the “strong” Q2 report. The analyst expects the growth of treprostinil-based products to largely be driven by the growing market potential for Tyvaso.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on UTHR:
- United Therapeutics reports Q2 EPS $5.24, consensus $4.50
- Liquidia says Federal Circuit affirms district court rulings in patent fight
- United Therapeutics says wins appeal in dry powder inhaler patent litigation
- Argus sees upside for United Therapeutics over the next year
- Liquidia price target lowered to $18 from $20 at BTIG
